Bristol-Myers Squibb is reportedly exiting its stake in a diabetes joint venture with AstraZeneca for $3 billion. Bristol-Myers shifted its focus from producing diabetes and hepatitis C treatment drugs to medicines harnessing the immune system to fight cancer.
Kombiglyze
Breaking News
- Donald Trump Is Eyeing Middle-Class Tax Cut Should He Take Down Joe Biden and Win Back the White House: Report
- Red Lobster Explores Bankruptcy Amid Mounting Debt: Reports
- US Plans to Lift Tariff Exceptions to Dominant Chinese Solar Panel Imports as Biden Accuses Beijing of 'Cheating' on Its Steel Trade Pactices
Subscribe to VCpost newsletter
Most Popular
- China Hits 2 U.S. Defense Companies With Sanctions For Selling Military Weapons to Taiwan
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- American Airlines Pilots Union Issues Urgent Safety Alert Over Maintenance Issues
- Trump Media’s First Auditor Quits After Just a Few Months on the Job: Report
- Social Security Benefits: 2025 COLA Predicted to Increase Amid Rising Inflation
- Convicted Fraudster Accused of Killing Wealthy Heiress Wife in Swimming Pool to Cash in on Over $4 Million Fortune
- Innocent Female Uber Driver, 61, Shot Dead by 81-Year-Old Ohio Man Who Was Targeted by Scammers
- Spirit Airlines Staff at Florida Airport Filmed Cursing a 'Karen' Passenger After Moaning About Her Flight
